Clinical Trial

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

Study acronym: PROGRESS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2016-12-09; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2017-08-16
Trial Details
NCT Number NCT02989025
Lead Sponsor University of Mississippi Medical Center
Conditions Pregnancy, Preeclampsia (PE)
Enrollment 60 participants
Start Date 2017-05-22
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-01